key: cord-0954260-bgc671mq
authors: Wang, Hongkai; Wu, Junlong; Wei, Yu; Zhu, Yao; Ye, Dingwei
title: Surgical Volume, Safety, Drug Administration, and Clinical Trials During COVID-19: Single-center Experience in Shanghai, China
date: 2020-04-21
journal: Eur Urol
DOI: 10.1016/j.eururo.2020.04.026
sha: f102ca6e700d8bdc4d18712bec5ef1a0566daba2
doc_id: 954260
cord_uid: bgc671mq

nan

. Patients with genitourological cancers are 8 facing delays to treatment and thus oncological outcomes 9 may be compromised. Here we report the impact of COVID-10 19 on surgical volumes, surgical safety, drug administration, 11 and clinical trials in our center, which is one of the largest 12 genitourinary cancer departments in China.

During the COVID-19 epidemic in China, we experienced 14 an 80% decrease in surgery volumes (Fig. 1A) E U R O P E A N U R O L O G Y X X X ( 2 0 1 9 ) X X X -X X X 

A familial cluster of pneumonia 71 associated with the 2019 novel coronavirus indicating person-to-72 person transmission: a study of a family cluster

Novel coronavirus(2019-nCoV): situa-74 tion report -70

SARS-CoV-2 transmission in patients 77 with cancer at a tertiary care hospital in Wuhan, China

Preserving clinical trial integrity 79 during the coronavirus pandemic

Surgical Volume, Safety, Drug Administration, and Clinical Trials During COVID-19: Single-center